HUBEI HONGYUAN PHARMACEUTICAL TECHNOLOGY CO., LTD. Financials Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Equities
301246
CNE100005ZB9
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.11 CNY | -3.07% |
|
-3.65% | -37.99% |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 10,392 |
| Enterprise Value (EV) 1 | 8,562 |
| P/E ratio | 116 x |
| Yield | 0.19% |
| Capitalization / Revenue | 5.06 x |
| EV / Revenue | 4.17 x |
| EV / EBITDA | 38.9 x |
| EV / FCF | -16.7 x |
| FCF Yield | -5.97% |
| Price to Book | 2.38 x |
| Nbr of stocks (in thousands) | 400,007 |
| Reference price 2 | 25.98 |
| Announcement Date | 4/22/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,320 | 1,574 | 1,303 | 1,578 | 2,064 | 2,055 |
| EBITDA 1 | 208.8 | 461.2 | 428.1 | 435.8 | 350.5 | 220.1 |
| EBIT 1 | 133.9 | 383.4 | 353.8 | 356.1 | 261.4 | 63.97 |
| Operating Margin | 10.14% | 24.35% | 27.15% | 22.57% | 12.67% | 3.11% |
| Earnings before Tax (EBT) 1 | 24.89 | 377.3 | 305.6 | 545 | 478 | 98.56 |
| Net income 1 | 12.12 | 314.4 | 257.2 | 493.8 | 434.8 | 87.17 |
| Net margin | 0.92% | 19.97% | 19.74% | 31.3% | 21.07% | 4.24% |
| EPS 2 | 0.0344 | 0.8913 | 0.7300 | 1.400 | 1.230 | 0.2246 |
| Free Cash Flow 1 | 266.8 | -210.6 | 213.5 | 53.33 | 121 | -511.5 |
| FCF margin | 20.22% | -13.38% | 16.39% | 3.38% | 5.86% | -24.89% |
| FCF Conversion (EBITDA) | 127.75% | - | 49.87% | 12.24% | 34.51% | - |
| FCF Conversion (Net income) | 2,201.12% | - | 83.01% | 10.8% | 27.82% | - |
| Dividend per Share | - | - | - | - | 0.1000 | 0.0500 |
| Announcement Date | 4/17/19 | 4/28/20 | 4/7/22 | 4/7/22 | 4/27/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 375 | 116 | - | - | - | - |
| Net Cash position 1 | - | - | 110 | 41.7 | 51 | 1,831 |
| Leverage (Debt/EBITDA) | 1.795 x | 0.2517 x | - | - | - | - |
| Free Cash Flow 1 | 267 | -211 | 213 | 53.3 | 121 | -512 |
| ROE (net income / shareholders' equity) | 2.05% | 40.8% | 24.4% | 34.5% | 22.9% | 2.69% |
| ROA (Net income/ Total Assets) | 5.16% | 14.7% | 13% | 10.6% | 5.18% | 0.84% |
| Assets 1 | 234.8 | 2,134 | 1,973 | 4,652 | 8,391 | 10,385 |
| Book Value Per Share 2 | 1.740 | 2.630 | 3.420 | 4.760 | 5.990 | 10.90 |
| Cash Flow per Share 2 | 0.4500 | 0.5600 | 0.7600 | 0.3400 | 1.120 | 1.050 |
| Capex 1 | 55.4 | 101 | 56.9 | 259 | 507 | 475 |
| Capex / Sales | 4.2% | 6.45% | 4.36% | 16.42% | 24.57% | 23.1% |
| Announcement Date | 4/17/19 | 4/28/20 | 4/7/22 | 4/7/22 | 4/27/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -37.99% | 919M | |
| +31.37% | 588B | |
| -2.80% | 364B | |
| +20.52% | 326B | |
| +5.55% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.84% | 167B | |
| +0.16% | 161B |
- Stock Market
- Equities
- 301246 Stock
- Financials Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
